Effectiveness and safety of tigecycline: Focus on use for approved indications

Clinical Infectious Diseases

Volumn 54, Issue 11, 2012, Pages 1672-1674

  Vardakas, Konstantinos Z ^a,b   Rafailidis, Petros I ^a,b   Falagas, Matthew E ^a,b,c  

^a ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^b HENRY DUNANT HOSPITAL   (Greece)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; TIGECYCLINE;

ABDOMINAL INFECTION; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; COMMUNITY ACQUIRED PNEUMONIA; DRUG APPROVAL; DRUG EFFICACY; DRUG FATALITY; DRUG INDICATION; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; GRAM NEGATIVE INFECTION; HUMAN; INFECTION; LETTER; MAJOR CLINICAL STUDY; META ANALYSIS (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SKIN INFECTION; SOFT TISSUE INFECTION; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG TOXICITY; HUMANS; MINOCYCLINE; TREATMENT OUTCOME; UNITED STATES;

EID: 84861016339     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis239     Document Type: Letter

References (21)

1. Food and Drug Administration. FDA drug-safety communication: increased risk of death with Tygacil (tigecycline) compared to other antibiotics used to treat similar infections. Available at: http://www.fda.gov/Drugs/DrugSafety/ ucm224370.htm. Accessed 5 November 2011.
2. Cai Y, Wang R, Liang B, Bai N, Liu Y. Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease. Antimicrob Agents Chemother 2011; 55:1162-72.
3. Yahav D, Lador A, Paul M, Leibovici L. Efficacy and safety of tigecycline: a systematic review and meta-analysis. J Antimicrob Chemother 2011; 66:1963-71.
4. Tasina E, Haidich AB, Kokkali S, Arvaniti-dou M. Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis. Lancet Infect Dis 2011; 11: 834-44.
5. Babinchak T, Zito E, Leister H. Global study of the efficacy of tigecycline versus ceftriax-one and metronidazole for the treatment of complicated intra-abdominal infections: Study 315. In: Abstracts of the Forty-ninth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 2009. Abstract L1-339. American Society for Microbiology, Washington, DC, USA.
6. Bergallo C, Jasovich A, Teglia O, et al. 308 Study Group. Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin. Diagn Micro-biol Infect Dis 2009; 63:52-61.
7. Breedt J, Teras J, Gardovskis J, et al. Tigecy-cline 305 cSSSI Study Group. Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam. Antimicrob Agents Chemother 2005; 49:4658-66.
8. Chen Z, Wu J, Zhang Y, et al. Efficacy and safety of tigecycline monotherapy vs. imipe-nem/cilastatin in Chinese patients with complicated intra-abdominal infections: a randomized controlled trial. BMC Infect Dis 2010; 10:217.
9. Fomin P, Beuran M, Gradauskas A, et al. 306 Study Group. Tigecycline is efficacious in the treatment of complicated intra-abdominal infections. Int J Surg 2005; 3:35-47.
10. McGovern P, Rill D, Zito E, et al. Efficacy of tigecycline versus ampicillin sulbactam or amoxicillin clavulanate to treat complicated skin and skin structure infections. Study 900. In: Abstracts of the Twentieth European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria. 2010. Abstract P1547. European Society of Clinical Microbiology and Infectious Disease, Basel, Switzerland.
11. Oliva ME, Rekha A, Yellin A, et al. 301 Study Group. A multicenter trial of the efficacy and safety of tigecycline versus imipe-nem/cilastatin in patients with complicated intra-abdominal infections. [Study ID Numbers: 3074A1-301-WW; ClinicalTrials. gov Identifier: NCT00081744]. BMC Infect Dis 2005; 5:88.
12. O'Riordan W, Surber J, Manos P, et al. Results of a phase 2 study comparing two doses of delafloxacin to tigecycline in adults with complicated skin and skin-structure infections. In: Abstracts of the Nineteenth
13. European Congress of Clinical Microbiology and Infectious Diseases, Helsinki, Finland, 2009. Abstract P1794. European Society of Clinical Microbiology and Infectious Disease, Basel, Switzerland.
14. Sacchidanand S, Penn RL, Embil JM, et al. Efficacy and safety of tigecycline monother-apy compared with vancomycin plus aztreo-nam in patients with complicated skin and skin structure infections: results from a phase 3, randomized, double-blind trial. Int J Infect Dis 2005; 9:251-61.
15. Tanaseanu C, Milutinovic S, Calistru PI, et al. 313 Study Group. Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia. BMC Pulm Med 2009; 9:44.
16. Towfigh S, Pasternak J, Poirier A, et al. A multicentre, open-label, randomized comparative study of tigecycline versus ceftriax-one sodium plus metronidazole for the treatment of hospitalized subjects with complicated intra-abdominal infections. Clin Microbiol Infect 2010; 16:1274-81.
17. Freire AT, Melnyk V, Kim MJ, et al. 311 Study Group. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. Diagn Mi-crobiol Infect Dis 2010; 68:140-51.
18. Sabol MB, Cooper A, Castaing N, et al. Phase 3 study comparing tigecycline (TGC) and ertapenem (ERT) in patients (pts) with diabetic foot infections (DFI) with and without osteomyelitis. In: Abstracts of the Forty-seventh Annual Meeting of the Infectious Diseases Society of America, Philadelphia, PA, 2009. Abstract LB-42.
19. Florescu I, Beuran M, Dimov R, et al. 307 Study Group. Efficacy and safety of tigecy-cline compared with vancomycin or linezolid for treatment of serious infections with methicillin resistant Staphylococcus aureus or vancomycin resistant enterococci: a phase 3, multicentre, double-blind, randomized study. J Antimicrob Chemother 2008; 62: i17-28.
20. Rosmarakis ES, Soteriades ES, Vergidis PI, Kasiakou SK, Falagas ME. From conference abstract to full paper: differences between data presented in conferences and journals. FASEB J 2005; 19:673-80.
21. Falagas ME, Rosmarakis ES. Clinical decision making based on findings presented in conference abstracts: is it safe for our patients?. Eur Heart J 2006; 27:2038-9.